Biopharmaceutical Products in the U.S. and European Markets - Current Year or Most Recent Edition.

Emphasis on biotechnology and commercial aspects - composition, activity, nomenclature, companies involved and relationships, manufacturing methods, patents/technology transfer, regulatory history/status, approved indications, market size/share, controversial aspects, etc. Over 500 product monographs (spanning 1,250 pages); up-to-date into July 1, 2006; includes all: recombinant and other proteins antibodies - monoclonal, radioimmune conjugates vaccines enzymes and toxins blood products - human and animal-derived cultured cell and tissue products and other products, e.g., vaccine adjuvants, antisense drugs Coverage - Includes all biopharmaceuticals approved in the U.S. and European Union, those with filings expected in 2006-7, formerly approved, and with applications denied or withdrawn Indexes - provide unprecedented access to biopharmaceutical products and companies; over 170 pages; 26,500+ index entries (ave. >50/product) Products/Active Agents (nomenclature), Class, Biological, Chemical, Medical, Market Size/Total Sales, Recombinant Expression/Host System, Regulatory/Status and Approval Date Indexes Company, Company Role, Country, State, and Marketing Territory Indexes New! Bonus Sections - Reviews and analyses of products, FDA approvals and biogenerics (follow-on proteins, biosimilars, etc.) 2 volumes, 1,480 pages - 8.5" x 11, hard cover bound